Adaptive Biotechnologies (ADPT) Total Current Liabilities (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Total Current Liabilities data on file, last reported at $87.0 million in Q1 2026.

• Quarterly Total Current Liabilities fell 0.91% year-over-year to $87.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87.0 million (down 0.91% YoY) and the FY2025 annual result came in at $89.9 million, down 8.3% from the prior year.
• Total Current Liabilities eased to $87.0 million in Q1 2026 per ADPT's latest filing, from $89.9 million in the prior quarter.
• The five-year high for Total Current Liabilities was $115.1 million in Q1 2022, with the low at $83.0 million in Q1 2024.
• Average Total Current Liabilities over 5 years is $94.4 million, with a median of $90.1 million recorded in 2023.
• Year-over-year, Total Current Liabilities slipped 21.7% in 2023 and advanced 11.4% in 2024.
• Adaptive Biotechnologies' Total Current Liabilities stood at $109.8 million in 2022, then retreated by 19.83% to $88.0 million in 2023, then rose by 11.4% to $98.1 million in 2024, then slipped by 8.3% to $89.9 million in 2025, then dropped by 3.23% to $87.0 million in 2026.
• Business Quant data shows ADPT's Total Current Liabilities at $87.0 million in Q1 2026, $89.9 million in Q4 2025, and $83.4 million in Q3 2025.